SCHEMBL2672809

SCHEMBL2672809

CCCCc1noc(C)c1/C=C/c1cc(C(=O)OCC)on1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.35
TP53 P04637 1/20 0.34
GAA P10253 1/20 0.34
BRD4 O60885 1/20 0.34
BRD2 P25440 1/20 0.34
CREBBP Q92793 1/20 0.34
CACNA1F O60840 2/20 0.33
CACNA1D Q01668 2/20 0.33
CACNA1S Q13698 2/20 0.33
CACNA1C Q13936 2/20 0.33
MAPT P10636 1/20 0.32
SMPD1 P17405 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
SLC26A6 Q9BXS9 1/20 0.31
HTT P42858 3/20 0.31
TDP1 Q9NUW8 1/20 0.31
LMNA P02545 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2672813 1.00 ALDH1A1 (0.35) ALDH1A1TP53GAABRD4BRD2
SCHEMBL2673644 0.87 HCAR2 (0.41) ALDH1A1TP53GAAMAPTSMPD1
SCHEMBL2673646 0.87 HCAR2 (0.41) ALDH1A1TP53GAAMAPTSMPD1
SCHEMBL7802004 0.80 POLB (0.46) ALDH1A1TP53GAASMPD1HTT
SCHEMBL13039697 0.74 ADORA3 (0.49) ALDH1A1MAPTCYP2C19LMNASMN1; SMN2
SCHEMBL195457 0.74 GABRA5 (0.41) MAPTSMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL195458 0.74 GABRA5 (0.41) MAPTSMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL196222 0.74 PRKCE (0.34) ALDH1A1TP53GAAMAPTHTT
SCHEMBL196160 0.73 ALDH1A1 (0.35) ALDH1A1TP53GAAMAPTCYP2C19
SCHEMBL108853 0.73 ALDH1A1 (0.42) ALDH1A1TP53GAACACNA1FCACNA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2398782-B1 ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2013-09-18 EP disclosed
US-8173652-B2 Isoxazole-isoxazoles and isoxazole-isothiazoles HOFFMANN-LA ROCHE INC. (US) 2012-05-08 US disclosed
EP-2398782-A1 ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094669-A1 ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210651-A1 ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES ROCHE PALO ALTO LLC 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210651-A1 ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES GABRA5, GABRA1, GABRA4 ALDH1A1 808/4885TP53 3475/4885GAA 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.